We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DNA Methylation Pattern May Be Biomarker for Cancer Detection

By LabMedica International staff writers
Posted on 17 Dec 2018
A team of Australian researchers has determined that a characteristic pattern of methylated DNA allows for easy detection of the genomes of cancerous cells and may serve as a universal biomarker for rapid diagnosis of many types of cancer.

Methyl groups regulate gene expression and thereby control how a cell functions. More...
Investigators at the University of Queensland (Brisbane, Australia) had reported previously that in healthy cells, methyl groups were spread out across the genome, but the genome of cancer cells were characterized by intense clusters of methyl groups at very specific locations. They named this distribution signature of the methylated DNA the "Methylscape."

The investigators examined the effect of levels and genomic distribution of methylcytosines on the physicochemical properties of DNA to detect the Methylscape biomarker. They found that DNA polymeric behavior was strongly affected by differential patterning of methylcytosine, leading to fundamental differences in DNA solvation and DNA-gold affinity between cancerous and normal genomes. One of the unique properties of the cancer cell Methylscape was its affinity for gold nanoparticles. Binding of DNA to such nanoparticles caused an immediate color change that was visible to the naked eye.

The investigators used electrochemical and colorimetric techniques to develop extremely simple, label-free, and naked eye platforms that could finely detect the Methylscape biomarker from cancer genomes based on the level of gold-DNA adsorption on planar and colloidal gold surfaces respectively. These assays were quick, i.e., analysis time less than 10 minutes, and required minimal sample preparation and small DNA input.

They tested these approaches on a large cohort of over 200 human samples (i.e., genomic DNAs extracted from cell-lines, tissues, and plasma) representing various cancer types. Results published in the December 4, 2018, online edition of the journal Nature Communications revealed that the accuracy of cancer detection was as high as 90%.

"Virtually every piece of cancerous DNA we examined had this highly predictable pattern. It seems to be a general feature for all cancer. It is a startling discovery," said senior author Dr. Matt Trau, professor of chemistry at the University of Queensland. "We certainly do not know yet whether it is the Holy Grail or not for all cancer diagnostics, but it looks really interesting as an incredibly simple universal marker of cancer, and as a very accessible and inexpensive technology that does not require complicated lab based equipment like DNA sequencing."

Related Links:
University of Queensland


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.